Arthur Raymond Beaubien has a daughter and lives in Ottawa, Canada. His initial degree was a B.A. in philosophy. He then pursued a career in science, earning a M.Sc. and a Ph.D. in pharmacology. He worked as a research scientist for Health Canada for over 25 years in the area of drug toxicology and is now retired. He has more than 25 scientific publications particularly in the areas of pharmacokinetics and in drug-induced hearing loss. Among his major published findings are: (1) the importance of first-pass binding to non-metabolising sites in the liver in the pharmacokinetics of the antidepressant drug imipramine (2) that the ototoxicity (destruction of hair cells in the inner ear leading to deafness) of the aminoglycoside antibiotic amikacin is a predictable function of the cumulative area under the plasma or perilymph concentration vs. time curve rather than blood levels per se (3) that amikacin has a half-life in the ototoxic compartment of about 80 days and (4) that it takes a minimum of 4 days to detect hearing loss once a toxic amount of amikacin has been administered. Although his Ph.D. degree is in pharmacology, he also has an extensive background in electrophysiology and computer programming. Upon retirement, he has devoted much of his time to writing and to his own spiritual development.